S. Dubey

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

Allen Lee Cohn, Josep Tabernero, Joan Maurel et al. · Annals of Oncology · 2013 · 89 citations · Full text

Medicine, Oncology, Pharmacology +14

Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression

Min Zhu, Rui Tang, Sameer Doshi et al. · British Journal of Cancer · 2015 · 41 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma

Brian I. Rini, Laurence Albigès, Xiaobin Tang et al. · Annals of Oncology · 2025 · 26 citations · Full text

Medicine, Immunology, Oncology +10

A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC).

D. Ross Camidge, Marc Ballas, S. Dubey et al. · Journal of Clinical Oncology · 2010 · 25 citations

Medicine, Oncology, Pharmacology +17

A comparative study of low dose weekly paclitaxel versus cisplatin with concurrent radiation in the treatment of locally advanced head and neck cancers

RK Jain, Pushpa Kirar, Gopila Gupta et al. · Indian Journal of Cancer · 2009 · 15 citations

Medicine, Oncology, Radiation Oncology +11